JPRN-UMIN000027425
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant setting - The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women
Kyoto Prefectural Universuty of Medicine0 sites100 target enrollmentMay 23, 2017
Conditionsbreast cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- breast cancer
- Sponsor
- Kyoto Prefectural Universuty of Medicine
- Enrollment
- 100
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Diagnosis of clinical or radiological disant metastasis before inclusion 2\) Invasive bilateral breast cancer 3\) Received prior treatment with intravenous bisphosphonates within the past 12 months 4\) Following diseases which may interfere with DXA scan such as severe scoliosis, vertebral diseases 5\) Current active dental problems including infection of the teeth or jawbone. Recent (within 6 weeks) or planned dental or jaw surgery(e.g., extraction, implants) 6\) Other conditions judged as inappropriate for the study by the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
The efficacy of the use of denosumab in the prevention of aromatase inhibitor-induced bone loss in postmenopausal women with hormone receptor-positive breast cancer who are currently on or will iniate an aromatase inhibitor in the adjuvant settingBreast CancerJPRN-UMIN000013863Department of Endocrine and breast cancer, Kyoto Prefectural University of medicine100
Completed
Not Applicable
Efficacy and safety of denosumab for the treatment of osteoporosis in patients with renal failureJPRN-UMIN000011992ephrology Center, Toranomon Hospital Nephrology Center, Toranomon Hospital Kajigaya40
Completed
Phase 3
A randomised, double-blind, placebo controlled trial to examine the effects of total oestradiol depletion on bone microstructure and the efficacy of denosumab in preventing microstructural bone decay in premenopausal women with early breast cancerpremenopausal osteoporosisbreast cancerMetabolic and Endocrine - Other endocrine disordersCancer - BreastMusculoskeletal - OsteoporosisACTRN12616001051437Professor Mathis Grossmann74
Completed
Not Applicable
The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patientsOsteoporosisJPRN-UMIN000022179Yujinkai Medical Corporation Yujin-yamazaki Hospital38
Not yet recruiting
Phase 2
se of Injection Denosumab in the treatment of Giant Cell Tumour.Health Condition 1: D169- Benign neoplasm of bone and articular cartilage, unspecifiedCTRI/2024/02/062905Dr Sanyam Rathi